Identification of nafamostat mesilate as an inhibitor of the fat mass and obesity-associated protein (FTO) demethylase activity.
Sign Up to like & getrecommendations! Published in 2019 at "Chemico-biological interactions"
DOI: 10.1016/j.cbi.2018.10.023
Abstract: Nafamostat mesilate is a serine protease inhibitor and used for the treatment of pancreatitis and cancers. The fat mass and obesity-associated protein (FTO) was identified to be a demethylase and played an important role in… read more here.
Keywords: protein; nafamostat mesilate; fat mass; mass obesity ... See more keywords
Use of nafamostat mesilate for anticoagulation during extracorporeal membrane oxygenation: A systematic review.
Sign Up to like & getrecommendations! Published in 2022 at "Artificial organs"
DOI: 10.1111/aor.14276
Abstract: BACKGROUND Extracorporeal membrane oxygenation (ECMO) represents an advanced option for supporting refractory respiratory and/or cardiac failure. Systemic anticoagulation with unfractionated heparin (UFH) is routinely used. However, patients with bleeding risk and/or heparin-related side effects may… read more here.
Keywords: nafamostat mesilate; membrane oxygenation; extracorporeal membrane; anticoagulation ... See more keywords
Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
Sign Up to like & getrecommendations! Published in 2022 at "PLoS ONE"
DOI: 10.1371/journal.pone.0267623
Abstract: Purpose To assess the efficacy of combination chemotherapy with nafamostat mesilate, gemcitabine and S-1 for unresectable pancreatic cancer patients. Materials and methods The study was conducted as a single-arm, single center, institutional review board-approved phase… read more here.
Keywords: nafamostat mesilate; unresectable pancreatic; pancreatic cancer; phase trial ... See more keywords